NeurAeon exists to eliminate late-stage protocol failures by subjecting every pharmaceutical development pathway to autonomous, adversarial scrutiny before physical resources are committed.
Pharmaceutical development loses $2.6 billion annually to late-stage protocol failures that could have been identified in simulation. We believe this is unacceptable.
Traditional R&D discovers errors during physical testing, when correction costs are exponential.
Batch failures, contaminated reagents, and discarded APIs represent environmental and financial catastrophe.
A single iteration cycle can delay patient access by months. We compress that to hours.
Four specialized agents. One uncompromising standard. Zero unvalidated protocols.
Validates synthetic routes, mechanism hypotheses, and reaction feasibility before resource allocation.
Validates impurity profiles, method robustness, and analytical control strategy sufficiency.
Assesses genotoxic impurity formation risks and safety pharmacology thresholds in silico.
Orchestrates workflow sequencing, resource allocation, compliance alignment, and execution gates.
"These agents do not assist scientists. They are scientists—computational workers bound by the same methodological rigor, operating at machine speed and machine scale."
Every agent operates under APS-9, our constraint-embedded instructional architecture that enforces clinical-grade precision and regulatory alignment across all simulations.
Unlike standard prompt engineering, APS-9 functions as a binding protocol layer—ensuring that outputs from our Research Scientist, QC, Toxicologist, and PI agents adhere to FDA, EMA, and ICH guidelines before they ever reach a human reviewer.
Measurable outcomes from simulation-first development
Discovery cycle acceleration through parallel agent simulation
Active protocol stress-tests running across our compute grid
Novel therapeutics validated by the Agentic Digital Lab
Experience how the Agentic Digital Lab can de-risk your pharmaceutical development pipeline before a single reagent is purchased.